Announcement that the cumulative reduction of shareholding in major subsidiary, OBIGEN Pharma, has reached more than 10%

Name of major subsidiary: OBIGEN Pharma, Inc. (hereinafter referred to as “OBIGEN Pharma”) Cause of occurrence (reduce the percentage of shareholding (or capital contribution to) or lose control ): reduce the percentage of shareholding Method of shareholding (or capital contribution) reduction (Please specify the date, reason, method, reduction percentage, volume, unit price, and total amount […]